FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563972945> ?p ?o ?g. }

• W2563972945 endingPage "259" @default.
• W2563972945 startingPage "256" @default.
• W2563972945 abstract "Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery.400 chemonaïve epithelial ovarian cancer patients, age≥18, ECOG PS 0-2 were eligible to receive C (AUC 5 d1, q21) plus P (175mg/m2 d1, q21) and B (15mg/kg d1 q21) for 6cycles followed by B maintenance until cycle 22nd.79 patients (20%) underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70% of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease ≤1cm was achieved in 64 patients (86.5%). Four percent of the patients experienced fever and 4% required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each.In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned." @default.
• W2563972945 created "2017-01-06" @default.
• W2563972945 creator A5004691735 @default.
• W2563972945 creator A5005815956 @default.
• W2563972945 creator A5011135357 @default.
• W2563972945 creator A5011959585 @default.
• W2563972945 creator A5015740152 @default.
• W2563972945 creator A5017440774 @default.
• W2563972945 creator A5020857846 @default.
• W2563972945 creator A5027542947 @default.
• W2563972945 creator A5029193050 @default.
• W2563972945 creator A5032866888 @default.
• W2563972945 creator A5040656664 @default.
• W2563972945 creator A5040915026 @default.
• W2563972945 creator A5044888208 @default.
• W2563972945 creator A5046097436 @default.
• W2563972945 creator A5060103872 @default.
• W2563972945 creator A5061939825 @default.
• W2563972945 creator A5062149201 @default.
• W2563972945 creator A5066888430 @default.
• W2563972945 creator A5070206722 @default.
• W2563972945 creator A5073892178 @default.
• W2563972945 creator A5079782055 @default.
• W2563972945 creator A5083659627 @default.
• W2563972945 date "2017-02-01" @default.
• W2563972945 modified "2023-09-30" @default.
• W2563972945 title "Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial" @default.
• W2563972945 cites W1979719314 @default.
• W2563972945 cites W1980499812 @default.
• W2563972945 cites W1983640410 @default.
• W2563972945 cites W2106767659 @default.
• W2563972945 cites W2113122060 @default.
• W2563972945 cites W2123604415 @default.
• W2563972945 cites W2135947389 @default.
• W2563972945 cites W2158272701 @default.
• W2563972945 cites W2168893449 @default.
• W2563972945 cites W2170928115 @default.
• W2563972945 cites W2171658624 @default.
• W2563972945 cites W2269087069 @default.
• W2563972945 cites W2316782539 @default.
• W2563972945 cites W2512953280 @default.
• W2563972945 cites W2518066588 @default.
• W2563972945 cites W632594043 @default.
• W2563972945 doi "https://doi.org/10.1016/j.ygyno.2016.12.011" @default.
• W2563972945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27993479" @default.
• W2563972945 hasPublicationYear "2017" @default.
• W2563972945 type Work @default.
• W2563972945 sameAs 2563972945 @default.
• W2563972945 citedByCount "35" @default.
• W2563972945 countsByYear W25639729452016 @default.
• W2563972945 countsByYear W25639729452017 @default.
• W2563972945 countsByYear W25639729452018 @default.
• W2563972945 countsByYear W25639729452019 @default.
• W2563972945 countsByYear W25639729452020 @default.
• W2563972945 countsByYear W25639729452021 @default.
• W2563972945 countsByYear W25639729452022 @default.
• W2563972945 countsByYear W25639729452023 @default.
• W2563972945 crossrefType "journal-article" @default.
• W2563972945 hasAuthorship W2563972945A5004691735 @default.
• W2563972945 hasAuthorship W2563972945A5005815956 @default.
• W2563972945 hasAuthorship W2563972945A5011135357 @default.
• W2563972945 hasAuthorship W2563972945A5011959585 @default.
• W2563972945 hasAuthorship W2563972945A5015740152 @default.
• W2563972945 hasAuthorship W2563972945A5017440774 @default.
• W2563972945 hasAuthorship W2563972945A5020857846 @default.
• W2563972945 hasAuthorship W2563972945A5027542947 @default.
• W2563972945 hasAuthorship W2563972945A5029193050 @default.
• W2563972945 hasAuthorship W2563972945A5032866888 @default.
• W2563972945 hasAuthorship W2563972945A5040656664 @default.
• W2563972945 hasAuthorship W2563972945A5040915026 @default.
• W2563972945 hasAuthorship W2563972945A5044888208 @default.
• W2563972945 hasAuthorship W2563972945A5046097436 @default.
• W2563972945 hasAuthorship W2563972945A5060103872 @default.
• W2563972945 hasAuthorship W2563972945A5061939825 @default.
• W2563972945 hasAuthorship W2563972945A5062149201 @default.
• W2563972945 hasAuthorship W2563972945A5066888430 @default.
• W2563972945 hasAuthorship W2563972945A5070206722 @default.
• W2563972945 hasAuthorship W2563972945A5073892178 @default.
• W2563972945 hasAuthorship W2563972945A5079782055 @default.
• W2563972945 hasAuthorship W2563972945A5083659627 @default.
• W2563972945 hasConcept C121608353 @default.
• W2563972945 hasConcept C126322002 @default.
• W2563972945 hasConcept C141071460 @default.
• W2563972945 hasConcept C2776694085 @default.
• W2563972945 hasConcept C2777802072 @default.
• W2563972945 hasConcept C2778239845 @default.
• W2563972945 hasConcept C2780427987 @default.
• W2563972945 hasConcept C2781100745 @default.
• W2563972945 hasConcept C2781413609 @default.
• W2563972945 hasConcept C2781451048 @default.
• W2563972945 hasConcept C31174226 @default.
• W2563972945 hasConcept C71924100 @default.
• W2563972945 hasConceptScore W2563972945C121608353 @default.
• W2563972945 hasConceptScore W2563972945C126322002 @default.
• W2563972945 hasConceptScore W2563972945C141071460 @default.
• W2563972945 hasConceptScore W2563972945C2776694085 @default.
• W2563972945 hasConceptScore W2563972945C2777802072 @default.
• W2563972945 hasConceptScore W2563972945C2778239845 @default.

• next